Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)
Elisa J Young, Sepehr N Tabrizi, Julia ML Brotherton, John D Wark, Jan Pyman, Marion Saville, C David Wrede, Yasmin Jayasinghe, Jeffrey Tan, Dorota M Gertig, Marian Pitts, Suzanne M Garland
BMC CANCER | BMC | Published : 2013
BACKGROUND: The quadrivalent human papillomavirus vaccine has been provided in Australia through the National Human Papillomavirus Vaccination Program since April 2007. National registry data demonstrates good coverage of the vaccine, with 73% of school-aged girls having received all three doses. To evaluate the effectiveness of the program, we propose a two-pronged approach. In one (sub study A), the prevalence of the vaccine-targeted human papillomavirus genotypes in a population cohort is being estimated, and will be analysed in relation to vaccination status, cervical cytology screening status, demographic, social, behavioural, medical and clinical factors. In sub study B, the distributi..View full abstract
JMLB, DMG, MS, and SMG were partner investigators on an Australian Research Council Linkage Grant 2008-2011 on which CSL Biotherapies was a partner organisation. SMG has received funding through her institution to conduct HPV vaccine studies for MSD and GSK, advisory board and lecture fees and grant support from CSL and GlaxoSmithKline, and Sanofi Pasteur and is a member of the Merck Global Advisory Board plus the Merck Scientific Advisory Committee for HPV.